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Abstract 
Trypanosoma cruzi is the causative agent of Chagas disease, the most important 
parasitic infection in Latin America. Despite a global research effort, there have been 
no significant treatment advances for at least 40 years. Gaps in our knowledge of T. 
cruzi biology and pathogenesis have been major factors in limiting progress. In 
addition, the extremely low parasite burden during chronic infections has 
complicated the monitoring of both disease progression and drug efficacy, even in 
predictive animal models. To address these problems, we genetically modified T. 
cruzi to express a red-shifted luciferase that emits tissue-penetrating orange-red 
light. Mice infected with these highly bioluminescent parasites can be monitored by 
in vivo imaging, with exquisite sensitivity. This technology has allowed chronic 
infections to be followed in real-time, identified the gastro-intestinal tract as a site of 
long-term parasite persistence, revealed the infection dynamics of genetically 
modified parasites, and played a central role in Chagas disease drug development 
programmes. However, a major drawback of bioluminescence imaging is that it does 
not allow visualisation of host:parasite interactions at a cellular level. To facilitate 
this, we generated T. cruzi strains that express a chimeric protein that is both 
bioluminescent and fluorescent. Bioluminescence allows the tissue location of 
infection foci to be identified, and fluorescence can then be exploited to detect 
parasites in histological sections derived from excised tissue. In this article, we 
describe in detail the in vivo imaging and confocal microscopy protocols that we 
have developed for visualising T. cruzi parasites expressing these dual-reporter 
fusion proteins. The approaches make it feasible to locate individual parasites within 
chronically infected murine tissues, to assess their replicative status, to resolve the 
nature of host cells, and to characterise their immunological context. 
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1. Introduction 
In Latin America, between 5 and 10 million people are infected with the protozoan 
parasite Trypanosoma cruzi, the aetiological agent of Chagas disease (1, 2). 
Throughout the region, it is a leading cause of heart disease. Because of migration, 
Chagas disease is also becoming a global public health concern, with for example, 
an estimated 300,000 infected individuals in the US (3), and 100,000 in Europe (4). 
In endemic regions, the parasite is spread predominantly by hematophagous 
triatomine bugs, although other means of transmission can include contaminated 
food and drink, organ transplantation, blood transfusion and the congenital route. 
 
T. cruzi is an intracellular parasite with an extremely wide host range, and has an 
ability to infect most mammalian cell types. In humans, the infection, which is 
considered to be life-long, passes through three defined stages. The initial acute 
phase begins 2-4 weeks post-infection, with parasites becoming widely disseminated 
in tissues and organs. Although the symptoms are usually mild, and resolve within a 
short time period, there are occasional fatalities due to myocarditis or 
meningoencephalitis. In the majority of cases, a robust immune response mediated 
by CD8+ IFN-+ T cells controls the infection (5, 6), which then proceeds to the 
asymptomatic chronic stage, where the parasite burden is extremely low and difficult 
to monitor. About 30% of those infected eventually develop debilitating chronic stage 
pathology, although this can take decades to become symptomatic. Most commonly, 
these individuals suffer from cardiomyopathy, and less frequently digestive tract 
megasyndromes (7-9). 
 
In those who develop chronic Chagas disease pathology, T. cruzi parasites are 
present in very small numbers and exist predominantly as intracellular amastigotes, 
with undefined tissue distribution.  This scarcity of parasites poses the questions – 
what actually drives disease pathology, and why is there such a wide spectrum of 
outcomes? For many years, autoimmunity was widely considered to be an important 
mechanism. This  hypothesis was based on observations that detectable T. cruzi are 
frequently absent in heart tissue derived from patients with cardiomyopathy, that host 
and parasite proteins can display cross-reactive epitopes, and that acute stage 
infections are characterised by polyclonal expansion of B- and T-cells, some of 
which may be autoreactive (10, 11). However, there is now a community-wide 
consensus that the role of autoimmunity has been overstated and that the continued 
presence of the parasite is a pre-requisite for pathology (12, 13). Other significant 
factors that have been associated with disease severity include host and parasite 
diversity, and immune status (14). Identifying the determinants of pathology in 
chronic Chagas disease will have major implications for treatment strategies. 
 
Progress in dissecting Chagas disease pathogenesis in humans has been hampered 
by the long-term nature of the infection, the complex and diverse outcomes, and by 
technical difficulties in establishing parasite burden and tissue distribution. Predictive 
animal models have therefore been of particular importance for research in this area. 
Recently, we developed a highly sensitive in vivo imaging system applicable to 
murine models of Chagas disease that exploits bioluminescent parasites that have 
been genetically modified to express an engineered red-shifted luciferase (15). This 
system allows chronic infections to be monitored in real time for periods of more than 
one year. Ex vivo imaging revealed that acute stage infections were pan-tropic, with 
all of the major organs and tissues highly infected. With progression to the chronic 
stage, the parasite burden fell by up to 3 orders of magnitude, with infections 
restricted predominantly to the stomach, colon and gut mesentery tissue, with other 
organs infected sporadically (16, 17). Transient bioluminescent foci could also be 
detected in peripheral sites, including the skin, although intriguingly, these were 
highly dynamic, appearing and disappearing over a period of hours.  
 
The production of luciferase-mediated bioluminescence by genetically modified 
parasites is an ATP-dependent process that requires the presence of the natural 
substrate luciferin. This mitigates against the use of this reporter in histological 
studies aimed at investigating host:parasite interactions at a cellular level. To 
overcome these limitations, we devised a “gene knock-in” strategy to generate 
parasites that expressed a dual-reporter fusion protein that was both bioluminescent 
and fluorescent (18). For the fluorescence activity, we integrated a gene encoding 
the highly stable monomeric protein mNeonGreen in-frame with the PpyRE9h red-
shifted luciferase sequence (19). Using this dual-reporter system, the location of 
infection foci in infected mice can be determined by in vivo bioluminescence imaging, 
with fluorescence then being exploited to visualise individual parasites in histological 
sections derived from the excised bioluminescent tissue. For the first time, this has 
allowed us to routinely detect and image infected host cells in tissue samples derived 
from mice in the chronic stage of Chagas disease, when the parasite burden is 
extremely low. The approach is both flexible and widely applicable to experimental T. 
cruzi infections, and has the capability to provide new insights into parasite biology 
and the host immune response. Here, we describe detailed procedures that can be 
used to exploit the bioluminescence/fluorescence reporter system. 
2. Materials   
1. T. cruzi epimastigote growth medium: RPMI-1640 (Sigma-Aldrich) supplemented 
with 10% (v/v) heat-inactivated (56oC/30 minutes) fetal bovine serum (FBS) 
(BioSera), 0.5% (w/v) tryptone (Sigma-Aldrich), 0.5% (w/v) HEPES (Sigma-Aldrich), 
0.03 M hemin (Biophoretics), 2 mM sodium glutamate, 2 mM sodium pyruvate, 2.5 
units ml-1 penicillin and 2.5 g ml-1 streptomycin (PenStrep, Gibco). 
2. Hygromycin (InvivoGen). 
3. L6 rat myoblast cell growth medium: T. cruzi epimastigote growth medium, without 
tryptone or hemin supplementation. 
4. Dulbecco’s Phosphate buffered saline (DPBS) (Sigma-Aldrich) 
5. ACK red cell lysis buffer (Gibco) 
6. Euthatal (Merial) 
7. d-luciferin (Syd Labs, Inc) 
8. Isofluorane in oxygen (Merial) 
9. Rely+On Virkon tablets (DuPont) 
10. Absolute ethanol (analytical reagent grade). 
11. Xylene Substitute (Sigma-Aldrich) 
12. Paraffin wax – Histosec®60 pastilles (without DMSO) solidification point 58-60°C 
(Merck) 
13. Tris buffered saline, pH 7.6  
14. Nalgene Mr FrostyTM freezing container (Sigma-Aldrich) 
15. Vectashield/DAPI (Vector Labs) 
16. Histological cassettes and lids (Simport) 
17. Microtome (Thermo Fisher Scientific) 
18. ImmEdge hydrophobic barrier pen (Vector Labs) 
19. In situ cell death detection kit, TMR red (Sigma-Aldrich) 
20. 5’-Ethynyl-2’-deoxyuridine (EdU) (Thermo Fisher Scientific) 
21. Click-iT Plus EdU Alexa Fluor 555 imaging kit (Thermo Fisher Scientific)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. Methods 
3.1 Parasite culturing 
T. cruzi is highly infectious and all life-cycle stages, both in vitro and in vivo, are 
potentially hazardous (insect stage epimastigote cultures can contain infectious 
metacyclic trypomastigotes). The lower limit for an infectious dose should be 
regarded as one parasite. It is therefore essential that all procedures involving live 
parasites are performed in a microbiological safety cabinet (Class II) and that all 
“sharps” precautions are meticulously observed. The biological hazard classification 
of T. cruzi (both wild type and genetically modified strains) varies between countries. 
However, until parasites have been permanently inactivated, it is advisable to work 
under CL3 conditions, taking particular care when handling infected blood and tissue 
samples. 
 
3.1.1. Culture epimastigotes of the bioluminescent/fluorescent T. cruzi CL-Luc:Neon 
strain in a closed cap culture flask at 28oC  in supplemented RPMI-1640 medium 
(20) (Materials), with 150 μg ml-1 hygromycin as the selective drug. Infectious 
metacyclic trypomastigotes (MTs) develop once the culture has entered stationary 
phase (approximately 2x107 parasites ml-1), and normally reach a frequency of 
~10%.   
 
3.1.2. Tissue culture trypomastigotes (TCTs) can be derived by infecting L6 rat 
myoblast cell monolayers (70% confluence) with stationary phase MTs, typically at a 
multiplicity of infection (MOI) between 1 and 5 (see note 1). Maintain the L6 cells in 
growth medium (Materials) in filter cap culture flasks at 37oC. 18 hours post-
infection, remove non-invasive parasites by washing the monolayer in plain 
RPMI1640 pre-warmed to 37ºC, and then incubate with fresh L6 growth medium. 
Change the medium every 2-3 days until extracellular TCTs are abundant, usually 6 
to 8 days post-infection. Harvest the extracellular TCTs from the medium by two-step 
centrifugation. First, spin at 100 g for 10 minutes in a 15 ml centrifuge tube, discard 
the pellet (mainly debris and detached cells), then centrifuge the supernatant at 
1,600 g for 10 minutes to produce an enriched TCT pellet. Resuspend the pellet in 1 
ml of L6 growth medium and count using a haemocytometer (use dilutions as 
necessary). Maintain the TCTs at 37ºC until required. To prepare infection inocula, 
centrifuge and resuspend the pellet in the required volume of DPBS. 
 
3.1.3. To cryopreserve TCTs, adjust parasite density to 5x106 ml-1 and add DMSO to 
7.5%. Transfer aliquots to cyrovials and place them in a Mr FrostyTM freezing 
container. Store for 24 hours at -80oC, then transfer to storage in liquid nitrogen. To 
revive parasites, transfer cryovials to a beaker containing tap water and thaw rapidly. 
Open the cap using a paper towel soaked in 70% ethanol. Transfer the contents to a 
15 ml tube containing 9 ml of L6 growth medium and centrifuge at 1,600 g for 10 
minutes to remove the cryopreservant. There should be a small pellet visible. Aspirate 
the supernatant taking care not to disrupt the pellet. Resuspend in 1 ml L6 growth 
medium, re-centrifuge at 10,000 g for 5 minutes, and resuspend the pellet in 250 l 
medium. Incubate for 1-2 hours at 37oC, then count using a haemocytometer (use 
dilutions as necessary). To prepare an infection inoculum, centrifuge and resuspend 
the pellet in the required volume of DPBS. 
 
3.2 Infection protocols 
All described procedures conform to the UK Animals (Scientific Procedures) Act 
1986 (ASPA) and were originally performed under UK Home Office project licences 
(PPLs 70/6997 and 70/8207). The techniques outlined have been applied to BALB/c, 
C57BL/6 and C3H/HeN mice (purchased from Charles River, UK), and to severe 
combined immunodeficiency (SCID) CB17 mice (bred in-house). Animals are 
maintained under specific pathogen-free conditions in individually ventilated cages. 
They experience a 12 hour light/dark cycle and have access to food and water ad 
libitum. Routinely, we use female mice, aged 8-12 weeks at the point of infection. 
Male mice have been used in some experiments, without a noticeable difference in 
the infection profile (17). 
 
3.2.1. For standard experiments, we use 1x104 in vitro derived TCTs (above) in 0.2 
ml DPBS to infect SCID mice via i.p. inoculation. Load the parasites into a 1 ml 
syringe, attach a 25G needle and eject any air/bubbles. Pick up the mouse by the 
base of the tail with your dominant hand. Slowly and gently force the mouse down 
onto the surface of the cage top, while gathering up the skin with your thumb and 
index finger. When you have a secure grip, lift the mouse off the cage top and turn 
your hand over, exposing the belly. Restrain the tail with either the ring or the little 
finger. If performed properly, the mouse should unable to move its head too far from 
side to side. Wipe its abdomen with alcohol, then inject 0.2 ml i.p and return to the 
cage. 
 
3.2.2. To monitor parasitemia, add 27 l ACK red blood cell lysis buffer (Materials) 
into a 1.5 ml microfuge tube. Perform a tail snip or tail vein puncture, collect 3 µl 
blood and mix with the ACK buffer using a P20 pipette. Wait 5 minutes, then count 
bloodstream form trypomastigotes (BTs) with a haemocytometer.  
 
3.2.3. 16-19 days post-infection, when parasitemia has exceeded 106 ml-1, collect 
blood from infected SCID mice by tail snip, tail vein puncture or cardiac puncture 
using a heparinized syringe. Check the parasite density by counting an aliquot as 
described above and adjust to 5x103 BTs ml−1 in DPBS. Use the BT suspension 
directly for i.p. infection of immunocompetent mice. If necessary, prepare large 
volumes of inocula in a 50 ml centrifuge tube. Use a pastette to evenly distribute 
parasites in suspension between inoculations.  
 
3.2.4. BALB/c mice are our main infection model and we typically infect with 1x103 
BTs via i.p injection. In other experiments, mice have been infected with up to 1x106 
MT, TCT or BT suspensions in 0.2 ml DPBS via i.p., i.v. or s.c. injection. The route of 
administration does not significantly affect the chronic infection profile (18), although 
mice infected with low numbers of parasites (<103) take longer to reach the peak of 
the acute stage. Infections by the oral route, either by oral gavage of 0.2 ml into the 
stomach (intra-gastric route), or by deposition of 20 µl in the oral cavity using a 
pipette (buccal route), tend to be less efficient, although the subsequent infection 
profile is similar to that produced by injection (21). Intra-gastric inoculation with BTs 
does not produce an infection. At experimental end-points, sacrifice mice by ex-
sanguination under terminal anaesthesia (euthatal; 15 l g-1 body weight). 
 
3.3. In vivo imaging 
3.3.1. For imaging, we use an IVIS Lumina II system (PerkinElmer) (as outlined in 
Figure 1A). Inject mice with 150 mg kg−1 d-luciferin i.p., leave for 5 minutes to allow 
luciferin to permeate all tissues, then anaesthetize using 2.5% (vol/vol) gaseous 
isofluorane in oxygen for 3-5 minutes.  
 
3.3.2. Acquire images using LivingImage 4.5 software 10–20 minutes after d-luciferin 
administration (see notes 4-6). Exposure times can vary between 1 second and 5 
minutes, depending on the intensity of the signal. Set binning to large, but reduce to 
medium or small if the signal reaches saturation (approx. 60,000 counts). Take 
dorsal and ventral images of each mouse (Figure 1B). Weigh the mice, revive in a 
cage or plastic box on a heated pad set to 37oC, and then return to their cages. 
Under these imaging conditions, the limit of detection when parasites are inoculated 
i.p. is close to 100 parasites, with a linear relationship between parasite burden and 
whole body bioluminescence at 1000 parasites and above (16). Our project licence 
allows each mouse to be imaged up to 40 times during its life-time.  
 
3.3.3. To estimate parasite burden in live mice, draw regions of interest (ROIs) using 
LivingImage v.4.5 and quantify bioluminescence as total flux (photons/second) 
summed from dorsal and ventral images. Determine the detection threshold for 
imaging using control uninfected mice of similar weight and age. 
 
3.4. Ex vivo imaging 
3.4.1. As a preliminary, weigh the mice, image as above, allow them to recover, and 
return to their cages for a minimum of 1 hour. Note the location of bioluminescence 
foci and the likely tissue/organ involved. 
 3.4.2. When ready to perform necropsy and ex vivo imaging, inject with a second 
dose of d-luciferin (as above) and place the mouse in a spare cage. After 5 minutes, 
euthanize by injection of euthatal (as above). When unresponsive to pinching of the 
paws, pin the body onto a dissection board. Perform ex-sanguination by cardiac 
puncture, or alternatively cut the skin from abdomen to snout along the midline, then 
along the limbs, and exsanguinate by severing the axial vessels on the right side. 
Cut upwards from the midline of the peritoneum and thorax, and across both sides 
from the diaphragm to expose the heart and inner thorax region. 
 
3.4.3. Prepare a solution of 0.3 mg ml-1 d-luciferin in DPBS, fill a 10 ml syringe and 
attach a 21G needle. Perfuse the heart via the left ventricle taking care not to 
remove the needle until perfusion is complete (see note 7). Clean up excess 
fluid/blood with pieces of absorbent paper towel and place in a discard bag. 
 
3.4.4. Lay out the Petri dish and its lid, and using a pastette, transfer 1 ml of 0.3 mg 
ml-1 d-luciferin onto each, distributed evenly in 10-12 pre-allocated spots. Conduct 
the necropsy as outlined below and transfer each organ or tissue sample to the Petri 
dish according to the arrangement shown in Figure 2 (see note 8). 
 
3.4.4.1. Remove the heart and dissect with a scalpel. Place each half into the dish in 
adjacent positions, exposing the internal structure, with the valves at the top.  
Remove the spleen and place in the dish with the thicker end to the left. Remove the 
lungs, a sample of the liver (from the largest lobe), a small sample of visceral fat 
(from the gonadal depot), and a sample of the skeletal muscle (left quadriceps). 
 3.4.4.2. Cut away the whole gut from the carcass, leaving the oesophagus attached 
to the stomach. Start by severing the oesophagus at the top of the thorax, then 
manoeuvre the scalpel into the abdomen by gently pulling from near the junction with 
the stomach. Detach the gut from the dorsal side of the peritoneum. Use two pairs of 
forceps to separate the mesenteries and detach them from the gut; as it is removed, 
simultaneously separate the oesophagus/stomach/small intestine from the 
caecum/colon. Position the colon in the dish as a straight horizontal line and position 
the connected caecum in a ‘C’ or ‘S’ shape, whichever is best to avoid kinks along its 
length. Transfer the stomach, oesophagus and small intestine as a single unit onto 
the dish. Position the distal end of the ileum first and gently guide the length of the 
small intestine into loops, positioned without gaps (as in Figure 2). Place the 
stomach slightly away from the ileum, with the oesophagus then arranged in a hook 
position, with all sections of the gut exposed as clearly as possible. 
 
3.4.5. Use a pastette to add up to a further 1 ml of 0.3 mg ml-1 d-luciferin carefully 
over the organs/tissues, ensuring that they remain bathed in the solution, but without 
moving out of position. Transfer the Petri dish to the IVIS Lumina II, and image for 5 
minutes on large binning (Figure 2). 
 
3.4.6. When imaging is complete, transfer the Petri dish/lid back to a safety cabinet 
and prepare the samples for histology (see below). All samples should be washed in 
DPBS prior to transfer to tubes/histology cassettes. Depending on the experiment, 
collect a pre-determined set of samples or collect based on the bioluminescence 
location. 
 3.4.7. To estimate tissue parasite loads, use LivingImage software to draw individual 
ROIs around each organ and tissue sample. Include an ROI to represent a blank 
area of the dish to serve as a background value. Measure the bioluminescence 
intensity expressed as radiance (photons second−1 cm−2 sr−1). Different tissues from 
uninfected control mice have slightly different background radiances, therefore 
normalize the data from infected mice using matching tissues from uninfected 
controls and use the fold-change in radiance (compared to the tissue-specific control 
reference values), as the final measure of ex vivo bioluminescence. 
 
3.5. Carcass imaging 
3.5.1. Following removal of the internal organs, position the carcass in the middle of 
a Petri dish lid, cut away and peel back the skin, exposing the internal cavity.  Cut 
the skin along the thighs and legs and pull back to reveal as much of the muscle as 
possible. Finally, to expose the internal regions of the neck/head, cut the skin along 
the midline of the throat and diagonally up towards the ears, exposing the salivary 
glands, while peeling the skin back.  Sever the ear canal and spread the skin flat 
against the Petri dish. Dissect the peritoneum from both sides and lay to the right of 
the carcass. Transfer the remaining liver, visceral and subcutaneous fat samples into 
the Petri dish lid alongside the carcass as shown in Figure 3A. 
 
3.5.2. Using a pastette, carefully bathe the carcass/tissues in up to 1 ml additional 
0.3 mg ml-1 d-luciferin solution.  Transfer the Petri dish lid to the imaging chamber 
and image for 5 minutes on large binning. Bioluminescent emissions are remarkably 
stable, and should remain readily detectable for more than 1 hour (Figure 3B), with 
d-luciferin solution being added to prevent drying out. 
 
3.6. Preparation of tissue for histological analysis and examination by confocal 
microscopy 
To ensure preservation of fluorescence in tissue samples derived from mice infected 
with parasites expressing the Luc:mNeonGreen fusion protein, we adapted 
methodology previously described by Nakagawa et al. (22).  
 
3.6.1. Identify fluorescent foci by ex vivo imaging (Figure 4A), and excise from tissue 
using a clean scalpel. Wash thoroughly with DPBS. For colon sections, place on filter 
paper and gently remove faecal pellets without tearing or damaging the tissue, using 
the angled seeker as a scraper. Fix tissue sections in pre-chilled 95% ethanol for 20-
24 hours at 4oC in histology cassettes.  
 
3.6.2. Dehydrate the tissue at room temperature using four changes of 100% ethanol 
over a period of 1 hour, in a dark container placed on a shaker. To clear the sample, 
wash with two changes of xylene for 12 minutes each, continuing on the shaker in 
the dark container. Embed at 56oC by placing the cassettes in two pots of melted 
paraffin for 12 minutes each. Once cooled, tissue/organ samples should be removed 
from the cassettes, gently positioned in wax block moulds and topped up with melted 
paraffin to prepare blocks for microtomy. Cool the wax blocks on a cold plate and 
store at room temperature in the dark to preserve fluorescence. 
 
3.6.3. Cut a series of 3 to 10 µm thick tissue sections from each wax mould using a 
microtome and transfer the ribbon of sliced sections to a water bath.  Select the 
desired section to mount and separate from the rest of the ribbon using tweezers, 
before easing the section onto a clean slide.  Slowly dip the slide into a warm water 
bath (42-46°C), to separate the section from the slide, and reposition the section on 
the slide in the correct orientation using tweezers. Leave mounted slides flat to dry 
and then place in a metal rack overnight at room temperature.  Place the metal rack 
on a hot plate (approximately 60oC) for 30-60 minutes to melt away excess paraffin, 
and then store at room temperature. For confocal imaging, further de-paraffinize the 
slides with two changes (30 seconds each) of xylene, three changes (1 minute each) 
of pre-chilled 95% ethanol, and three changes (1 minute each) of pre-chilled Tris-
buffered saline, pH 7.6 (TBS). Once dry, mount the slides using vectashield/DAPI, by 
pipetting an adequate volume on top of the tissue section. Carefully place a cover 
slip on top. Avoid bubbles and seepage of mounting fluid from the edges. Seal the 
edges using clear nail varnish and leave to dry, before storing at 4oC in the dark until 
required.  
 
3.6.4. For imaging (Figure 4B), we use a Zeiss LSM510 Axioplan confocal laser 
scanning microscope, with the associated software. First, scan the sections using 
the GFP/FITC filter to identify putative parasites. Check for the presence of 
kinetoplast (k) DNA (mitochondrial DNA) using the DAPI filter to distinguish parasites 
from any auto-fluorescent particles. Then, obtain phase images at 40x magnification 
to enable orientation of the tissue section and identification of specific 
layers/structures. Take images for DAPI and mNeonGreen and then switch to 63x or 
100x objective and zoom-in on the parasites. Image in three dimensions (z-stacking) 
to allow precise counting of amastigotes, with the appropriate scan zoom selected 
for the particular cell/number of parasites. Images can be analysed and scale bars 
added using the Zeiss LSM image browser software, and exported as JPEG or TIF 
files for analysis using other software such as image J (Figure 4B). 
 
3.7 Assessing parasite replication: TUNEL assays  
The TUNEL assay uses the enzyme terminal deoxynucleotidyl transferase to add 
fluorescently labelled UTP analogues to 3’ hydroxyl groups generated at sites of 
DNA breaks (23). It is routinely used to characterise apoptosis in mammalian cells. 
In trypanosomatids, this assay can be used to identify parasites undergoing kDNA 
replication at the time of tissue fixation (18, 24). The kDNA consists of minicircles 
(~0.5-2 kb) and maxicircles (20-40 kb). The minicircles are present in thousands of 
copies per cell in a large catenated network (25), reminiscent of chain mail armour. 
To be replicated, each circle must be detached from this network, and copied to 
produce two daughter circles, then re-attached. During this process, new strands 
transiently possess single strand DNA breaks. These nicks can be labelled using the 
TUNEL assay; therefore TUNEL positive kinetoplasts identify parasites actively 
replicating their mitochondrial DNA at the point of tissue fixation. 
 
3.7.1. Deparaffinise slides as outlined in section 3.6.3. Draw around the relevant 
section with a hydrophobic pen, then permeabilize in 0.1% TritonX-100/PBS for 5 
minutes. Wash 3 times with PBS. To each section, add an appropriate volume of 
TUNEL reaction mixture (10-50 μl for an average section; In Situ Cell Death 
Detection Kit, Materials) and overlay the slide with a coverslip to ensure that the 
reaction mix is evenly distributed. This also minimises the volume of reaction mix 
required. Incubate the reaction for 1-2 hours at 37°C in a darkened humid chamber. 
Remove the coverslip by floating it off in PBS (this is easily done in a Petri dish), 
being careful not to damage the tissue section. Wash the slides three times in PBS 
and mount in Vectashield/DAPI. Examine the slides by confocal microscopy. 
 
3.8. Assessing parasite replication: Nucleoside analogue incorporation. 
Nuclear DNA replication can be measured by incorporation of nucleoside analogues 
in vivo, which are then detectable after fixation and sectioning (26-28). Two methods 
are commonly used; incorporation of 5-bromo-2’-deoxyuridine (BrdU) followed by 
antibody detection, or incorporation of 5-ethynyl-2’deoxyuridine (EdU), which is 
detected by direct fluorescent labelling using copper-catalysed click-chemistry. The 
BrdU method requires harsh denaturation conditions to facilitate access of the 
antibody to the modified base. This is incompatible with maintaining the fluorescence 
of the mNeonGreen reporter protein. For this reason, we use EdU incorporation, 
since labelling can occur without DNA strand separation, and the click reaction has 
no effect on the fluorescent protein. 
 
3.8.1. Administer EdU (12.5 mg kg-1 in DPBS) to infected mice by i.p. injection. To 
label replicating parasites, we inoculate EdU 24, 48 or 72 hours prior to sacrifice. To 
detect parasites which have undergone one round of replication, but then become 
dormant, we administer a single dose of EdU at least 7 days before.  
 
3.8.2. After sacrifice, prepare tissue sections as described in sections 3.4. and 3.6 
(Figure 5A). Deparaffinise slides as outlined in section 3.6.3, draw around the 
section with a hydrophobic pen, permeabilize in 0.1% TritonX-100/PBS for 5 minutes 
and then wash 3 times with PBS. Prepare the Click-iT reaction cocktail (Materials) – 
as these kits are expensive, we prepare the minimum volume required for the 
sections being labelled. Only prepare the cocktail when the slides are ready for 
labelling, as it has to be added within 15 minutes. Add an appropriate volume of the 
reaction cocktail (up to 20 μl for an average section). Overlay the slide with a 
coverslip to ensure that the reaction mix is evenly distributed across the section. 
Incubate at room temperature for 30 minutes. Remove the coverslip by floating it off 
in PBS (in a petri dish), being careful not to damage the tissue section. Wash the 
slides three times in PBS and mount in Vectashield/DAPI. Examine the slides by 
confocal microscopy (Figure 5B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Notes 
1. To maximise the yield and purity of TCTs, use freshly seeded L6 cell monolayers 
and a MOI of 1. For infections on the same day, seed cells at 1.8x105 ml-1, incubate 
for 6 hours, then add parasites. For infections the following day, seed at 8x104 ml-1 
and incubate overnight. 
 
2. To ensure reproducibility, we strongly recommended generating a large batch of 
TCTs that can be cryopreserved for future experiments. 
 
3. Needles narrower than 25G may damage trypomastigotes and perturb infectivity. 
Avoid drawing parasites repeatedly through needles. To minimise inoculum leakage, 
employ proper injection technique. Place your gloved thumb over the injection site 
for 10-15 seconds after withdrawing the needle, keeping the animal angled with its 
head around 45 degrees downwards. To avoid the risk of self-infection, never place 
a syringe needle back into the sheath, instead put directly into a sharps bin.  
 
4. Non-infected control mice should be imaged as part of each imaging session. 
These data allow establishment and monitoring of the background luminescence and 
also control for any effects of luciferase injections or anaesthesia on downstream 
read-outs, such as pathology. 
 
5. The optimum imaging window is 10–20 minutes after injection of d-luciferin. 
However, the bioluminescence signal from live animals decreases relatively slowly 
and is still approximately 80% of the maximum after 30 minutes (15).  
 
6. For unbiased image analysis in LivingImage, adjust the pseudocolour scale levels 
to hide the bioluminescence signal before drawing ROIs.  
 
7. For effective perfusion, ensure that the solution is at ambient temperature. Check 
that the needle is correctly positioned by visualising inflation of the heart chambers 
and then increase the pressure on the syringe very gradually, administering around 1 
ml every 3 seconds. The lungs and liver should become paler. If this does not occur, 
re-position the needle, without removing. 
 
8. Organs and tissue samples can be weighed prior to transfer into a Petri dish.  
 
9. For a good quality confocal microscopy images, apply the Vectashield mounting 
solution to samples recently rehydrated with PBS. Apply 8–10 µl (depending on the 
size of the sample) in a continuous strip along the centre, and then lower the cover 
slip slowly from one end, without forming bubbles. Remove the excess mounting 
solution on the sides of the coverslip and seal with nail varnish. 
   
10. For thin sections (<10μM), the TUNEL assay may label the nuclei of many 
mammalian cells (29). This is an artefact due to the mechanical cleavage of DNA 
during sectioning, as mammalian cell nuclei may have a diameter that exceeds the 
thickness of the section. Amastigotes are too small for this to be a major problem, 
unless one is cleaved during the microtome sectioning. Labelling of replicating 
amastigotes should be restricted to the kDNA. Nuclear DNA labelling only occurs in 
dead or dying parasites after treatment with some drugs, depending on whether the 
mode of death induces DNA breaks in the nuclear genome. 
 11. EdU will also label replicating mammalian cells (Figure 5B), a phenomenon that is 
most obvious in sections of gut tissue, where epithelial cells are constantly replaced. 
This provides a useful positive control for labelling. In terminally differentiated tissue, 
such as muscle, there should be very few labelled host nuclei, an exception being 
infiltrating immune cells. EdU incorporation occurs during DNA synthesis and both 
kDNA and nuclear DNA will be labelled in replicating parasites, although the relative 
extent of this in each organelle will depend on the cell-cycle phase during EdU 
exposure. Labelled parasites have been detected in all tissue types so far examined, 
suggesting that EdU is widely distributed in mice. 
 
12. For slides to be stained with antibody after labelling by TUNEL or EdU, this should 
be done after the TUNEL/EdU labelling reactions, prior to mounting the slides. These 
slides must be kept in the dark during all stages of antibody staining, as they already 
carry two fluorescent labels (mNeonGreen and TUNEL/EdU). 
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Figure 1. In vivo imaging of Trypanosoma cruzi infection. (A) Outline of standard 
procedures. Mice are infected with bioluminescent parasites (16), inoculated with 
luciferin at various time-points thereafter, with images acquired using the IVIS 
Lumina II system (PerkinElmer). Mice can be imaged multiple times over periods of 
longer than 1 year. (B) Using bioluminescence imaging to assess drug-treatment of 
chronic stage T. cruzi infection. BALB/c mice (day 14 post-infection) were treated 
with benznidazole (100 mg kg-1, orally, once daily) for 5 days. They were monitored 
regularly by bioluminescence imaging (left hand image, non-treated mice; right hand 
image, benznidazole-treated). All mice were immunosuppressed on days 135, 139 
and 143 using cyclophosphamide (200 mg kg-1 i.p). Heat-maps are on log10 scales 
and indicate intensity of bioluminescence from low (blue) to high (red). 
 
Figure 2. Ex vivo imaging of tissues and organs from Trypanosoma cruzi infected 
mice, harvested at various points post-infection. In the chronic stage (day 112), 
parasites are restricted predominantly to the colon and/or stomach, with other 
organs/tissues infected only sporadically (see ref. 17 for further examples). 
Treatment with the immunosuppressive drug cyclophosphamide promotes expansion 
and dissemination of the infection. During the acute stage (day 14), all organs and 
tissues are infected. The inset (right) shows the arrangement of organs and tissues. 
 
Figure 3. Imaging the carcass of mice chronically infected with Trypanosoma cruzi. 
(A) The carcasses from mice that were uninfected (left), infected (centre), and 
infected then immunosuppressed (left), were prepared for bioluminescence imaging 
as described in section 3.5. (B) Bioluminescence is remarkably stable over time. 
Skin tissue containing bioluminescent T. cruzi foci were imaged over the time period 
indicated (minutes). Arrows show points when fresh d-luciferin was added. 
 
Figure 4. (A) Bioluminescence imaging of organs from a chronically infected BALB/c 
mouse (day 117 post-infection). Organs were arranged as shown in Figure 2. A 
tissue sample (outlined in red) was excised from the stomach antrum and prepared 
for confocal microscopy (section 3.6.). (B) Images of tissue section obtained using 
the Zeiss LSM 510 confocal microscope. Upper images: low magnification showing 
the phase image for tissue structure, DAPI stained cell nuclei, mNeonGreen 
expressing parasites, and a merger of all three. The bar represents 50 µm. Lower 
images: Higher magnification of the area outlined in the dotted blue box showing 
mNeonGreen and DAPI merged images. The arrows indicate the kDNA (K), which 
appears as a rod-shaped DNA-containing structure in 2-dimensional images, 
indicative that the green fluorescent signals are derived from parasites. The image 
bars represent 5 µm. 
 
Figure 5. (A) Bioluminescence imaging of organs from an acutely infected CB17 
SCID mouse (day 15 post-infection) which was injected with 12.5 mg kg-1 EdU, 6 
hours prior to sacrifice. Rectal tissue (circled in red) was excised and prepared for 
analysis by confocal microscopy. (B) Low magnification showing general DNA 
staining with DAPI, replicating DNA stained with EdU, parasites expressing 
mNeonGreen (the box indicates the cluster shown in C), and a phase image of the 
tissue. The final image was generated by merging all four channels. The bar 
represents 50 µm. In the EdU panel, the white arrows indicate replicating murine 
epithelial cells. Compare the epithelial layers to the terminally differentiated muscle 
layer - EdU staining is specific to epithelial nuclei and absent from muscle cell nuclei. 
The white triangles indicate labelled T. cruzi clusters within the muscular layer, 
containing parasites that were undergoing DNA replication during the 6 hours 
following EdU administration. (C) Images of one of the parasite clusters at a higher 
magnification. The white arrows indicate that both the nuclear (N) and kinetoplast (K) 
genomes are labelled by EdU. The bar represents 10 µm. 
 
   
  
